Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The incidence of endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injections has been reported to be 0–0.16%, but can result in severe and permanent loss of vision.1 ,2 These injections are administered in different clinical settings, like doctors’ office suites as well as operating rooms. We report the incidence, clinical and microbiological profile of endophthalmitis following anti-VEGF injections administered in an ambulatory surgical centre (ASC) facility, its management and outcome.
A retrospective review of medical records of patients diagnosed as endophthalmitis following intravitreal anti-VEGF injections administered between January 2007 and May 2012 at four tertiary eye-care centres in India were performed. Appropriate approval was obtained from the institutional review boards. The clinical, microbiological profile and management of all cases (Otable 1) were analysed. The best corrected visual acuity (BCVA) at the time of diagnosis of endophthalmitis and last follow-up (figure 1) after management of endophthalmitis were compared using Wilcoxon signed-rank test. Statistical analysis was done using SPSS V.17.0 software version. A favourable visual outcome …
Competing interests SJ is an advising committee member of Ozurdex for Allergan. TD is on the advisory boards of Novartis, Alcon and Allergan.
Ethics approval Hyderabad Eye Research, Ethics Committee, L V Prasad Eye Institute.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement The first and only submission of this data was submitted to BJO. Previously, it had been presented at the ISO-HK conference in Hong Kong in December 2012, and at the AIOS-2013 in Hyderabad, India, in January 2013.